APA (7th ed.) Citation

Kohli, P., Desai, N. R., Giugliano, R. P., Kim, J. B., Somaratne, R., Huang, F., . . . Sabatine, M. S. (2012). Design and Rationale of the LAPLACE‐TIMI 57 Trial: A Phase II, Double‐Blind, Placebo‐Controlled Study of the Efficacy and Tolerability of a Monoclonal Antibody Inhibitor of PCSK9 in Subjects With Hypercholesterolemia on Background Statin Therapy. Clinical cardiology (Mahwah, N.J.), 35(7), 385-391. https://doi.org/10.1002/clc.22014

Chicago Style (17th ed.) Citation

Kohli, Payal, et al. "Design and Rationale of the LAPLACE‐TIMI 57 Trial: A Phase II, Double‐Blind, Placebo‐Controlled Study of the Efficacy and Tolerability of a Monoclonal Antibody Inhibitor of PCSK9 in Subjects With Hypercholesterolemia on Background Statin Therapy." Clinical Cardiology (Mahwah, N.J.) 35, no. 7 (2012): 385-391. https://doi.org/10.1002/clc.22014.

MLA (9th ed.) Citation

Kohli, Payal, et al. "Design and Rationale of the LAPLACE‐TIMI 57 Trial: A Phase II, Double‐Blind, Placebo‐Controlled Study of the Efficacy and Tolerability of a Monoclonal Antibody Inhibitor of PCSK9 in Subjects With Hypercholesterolemia on Background Statin Therapy." Clinical Cardiology (Mahwah, N.J.), vol. 35, no. 7, 2012, pp. 385-391, https://doi.org/10.1002/clc.22014.